BASEL, Switzerland,
Sept. 28 /PRNewswire-FirstCall/ -
Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES)
discloses its list of licenses.
NEURO # 1
SymPath(R)
TO EVALUATE THE SYMPATHETIC NERVOUS SYSTEM THROUGH THE ENZYME,
DOPAMINE Beta- HYDROXYLASE (DBH), THAT IS RELEASED WITH
NORADRENALINE WITHIN THE BLOOD AND DISTINGUISH BETWEEN DEPRESSIVE
STATES AND ANXIOUS DISORDERS.
NEURO # 2
AXIS(TM)
TO QUANTITATIVELY AND DIRECTLY EVALUATE THE
HYPOTHALAMO-PITUITARY ADRENAL AXIS THROUGH ENDING MOLECULES FORMED
FROM THE RELEASED ACTH WITHIN THE BLOOD AND ACTING ON DESMOLASE
ENZYME ACTIVITY, REQUIRING CHOLESTEROL BIOAVAILABILITY.
NEURO # 3
TETRIC(TM)
TO UNDERSTAND THE RELATIONSHIP BETWEEN CONSTITUTIVE &
INDUCTIVE DBH ENZYME IN ORDER TO DISCRIMINATE PSYCHOAFFECTIVE AND
MENTAL DISTURBANCES, THROUGH SIEVING MOLECULAR WEIGHT.
NEURO #4 and #5
ARE ONE PLATFORM FOR ALL OF THEM: 5-HT / 5HIAA DA / DOPAC / HVA
NA / VMA / A MELATONIN TO UNDERSTAND THE RELATIONSHIP BETWEEN
NEUROTRANSMITTERS, THE TURNOVER OF THEIR METABOLITES, AND TO FIGURE
OUT THE CLINICAL PREDOMINENCE
NEURO # 6
TRYPTYR
TO EVALUATE THE BIOAVAILIBILITY OF TWO MAIN NEURO-TRANSMITTERS
SUBSTRATES AND THEIR IMPACT IN BRAIN 5-HT AND NA SYNTHESIS.
NEURO #7
DIVAN
TO EVALUATE THE BIOAVAILABILITY OF THE EIGHT (8) ELECTROLYTES
AND THEIR RELATIONSHIPS INVOLVED IN THE CNS.
NEURO # 8
GACHA
TO EVALUATE THE GABA AND ACETHYLCHOLINE RELATIONSHIP AT THE
CELLULAR ENERGETIC CAPACITY.
NEURO # 9
FREERAD
TO MEASURE THE FREE RADICALS AND DETERMINE THEIR PREDOMINANCE IN
REGARDS TO THE AXIS ACTIVITY.
NEURO # 10
MAOS
TO DETERMINE THE MAO TYPE A OR B ACTIVITY AND TO DEFINE THE
CLINICAL PATIENT PROFILE IN RESPECT TO EXPECTED DIAGNOSIS AND
THERAPEUTIC APPROACHES.
NEURO # 11
NEURENDOM
TO DEFINE THE MALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE
NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.
NEURO # 12
NEURENDOF
TO DEFINE THE FEMALE NEUROENDOCRINE PROFILE IN ORDER TO DIAGNOSE
NEURO-PSYCHO-AFFECTIVE ENDOCRINE ILLNESS.
SOURCE Neuro-Biotech Corp.
Copyright . 28 PR Newswire